BioWorld

Jan. 28, 2008

Vertex Phase III, HGS News Spark Ever-Busy HCV Space

Vertex Pharmaceuticals Inc.'s unveiling last week of the Phase III program for the protease inhibitor telaprevir - the latest volley in the battle for a better hepatitis C virus therapy - brought cheers, muted somewhat by the inclusion of a 48-week treatment study, added to the larger test lasting half that long. (BioWorld Financial Watch) Read More

U.S. Public Offering Performance By Underwriter: January 1 December 31, 2007

ALL OFFERINGS, ALL UNDERWRITERS, RANKED BY AFTER-MARKET PERFORMANCE * #

UNDERWRITERS' PERFORMANCE ON IPOS: FULL CREDIT TO LEAD UNDERWRITER, RANKED BY GROSS PROCEEDS

UNDERWRITERS' PERFORMANCE ON IPOS: FULL CREDIT TO LEAD UNDERWRITER, RANKED BY AFTER-MARKET PERFORMANCE

IPOS: FULL CREDIT TO ALL UNDERWRITERS, RANKED BY GROSS PROCEEDS

IPOS: FULL CREDIT TO ALL UNDERWRITERS, RANKED BY AFTER-MARKET PERFORMANCE

PERFORMANCE ON ALL PUBLIC OFFERINGS: FULL CREDIT TO LEAD UNDERWRITER, RANKED BY GROSS PROCEEDS

PERFORMANCE ON ALL PUBLIC OFFERINGS: FULL CREDIT TO LEAD UNDERWRITER, RANKED BY AFTER-MARKET PERFORMANCE

Today's news in brief

BioWorld

BioWorld briefs for July 21, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

LIT-002 is strong candidate for autism and neuropathic pain

BioWorld Science

Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

New biomarker may improve RSV drug screening

BioWorld

Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The...